// App-Quantinova.ai

BSH2020‐OR‐022 : Ixazomib‐dexamethasone versus physician's choice in patients with relapsed/refractory systemic AL amyloidosis: primary data from the phase 3 TOURMALINE‐AL1 trial

Researchers

Presenter

  • A. D. Wechalekar

Principal Investigators

  • A. Dispenzieri

  • E. Kastritis

  • S. O. Schnland

  • K. Kim

  • V. Sanchorawala

  • H. J. Landau

  • F. Kwok

  • K. Suzuki

  • R. L. Comenzo

  • D. Berg

  • G. Liu

  • D. V. Faller

  • G. Merlini

Medical Centers

  • National Amyloidosis Centre, the Royal Free London NHS Foundation Trust, University College London,London,United Kingdom

  • Mayo Clinic, Rochester, MN

  • National and Kapodistrian University of Athens, Athens, Greece

  • Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Division of General Pediatrics, Boston University School of Medicine/Boston Medical Center, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Westmead Amyloidosis Service, Westmead Hospital, on behalf of the Australian Amyloidosis Network, Sydney, Australia

  • Japanese Red Cross Medical Center, Tokyo, Japan

  • John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

Locations

  • United Kingdom

  • United States

  • Greece

  • Germany

  • Australia

  • Japan

  • Italy

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Multiple Myeloma

  • Congestive heart failure

  • AL Amyloidosis

  • Amyloid disease

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Thalidomide

  • Melphalan

  • Ixazomib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved